Clinical Trial Update: FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and pharmacokinetics of single and repeat oral doses of FDL169 in healthy volunteers has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• FDL169

Snippet

Sponsor: Flatley Discovery Lab LLC | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED